journal article·2022-12Open access

Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2

Jeonghwan Kim, Antony Jozic, Anindit Mukherjee, Dylan Nelson, Kevin Chiem, Md Siddiqur Rahman Khan, Jordi B. Torrelles, Luis Martinez‐Sobrido, Gaurav Sahay

Advanced Science· Volume 9· Issue 35

Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can cause lethal pulmonary damage in humans. It contains spike proteins on its envelope that bind to human angiotensin‐converting enzyme 2 (hACE2) expressed on airway cells, enabling entry of the virus, and causing infection. The soluble form of hACE2 binds SARS‐CoV‐2 spike protein, prevents viral entry into target cells, and ameliorates lung injury; however, its short half‐life limits therapeutic utilities. Here, synthetic mRNA is engineered to encode a soluble form of hACE2 (hsACE2) to prevent viral infection. A novel lipid nanoparticle (LNP) is used for packaging and delivering mRNA to cells to produce hsACE2 proteins. Intravenously administered LNP delivers mRNA to hepatocytes, leading to the production of circulatory hsACE2 initiated within 2 h and sustained over several days. Inhaled LNP results in lung transfection and secretion of mucosal hsACE2 to lung epithelia, the primary site of entry and pathogenesis for SARS‐CoV‐2. Furthermore, mRNA‐generated hsACE2 binds to the receptor‐binding domain of the viral spike protein. Finally, hsACE2 effectively inhibits SARS‐CoV‐2 and its pseudoviruses from infecting host cells. The proof of principle study shows that mRNA‐based nanotherapeutics can be potentially deployed to neutralize SARS‐CoV‐2 and open new treatment opportunities for coronavirus disease 2019 (COVID‐19).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies · SARS-CoV-2 detection and testing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences College of Pharmacy Robertson Life Sciences Building Oregon State University Portland OR 97201 USA

High‐Throughput Screening Services Laboratory College of Pharmacy Oregon State University Corvallis OR 97331 USA

Disease Prevention and Intervention and Population Health Programs Texas Biomedical Research Institute San Antonio TX 78227 USA

Department of Biomedical Engineering Robertson Life Sciences Building Oregon Health & Science University Portland OR 97201 USA

Department of Ophthalmology Casey Eye Institute Oregon Health & Science University Portland OR 97239 USA

Funding

Cystic Fibrosis Foundation

References (62)

Show source-provided references
1. 10.1016/S1473-3099(20)30120-110.1016/S1473-3099(20)30120-1 ↗
2. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
3. 10.1126/science.abb276210.1126/science.abb2762 ↗
4. 10.1038/s41423-020-0374-210.1038/s41423-020-0374-2 ↗
5. 10.1016/S0014-5793(02)03640-210.1016/S0014-5793(02)03640-2 ↗
6. 10.1002/path.216210.1002/path.2162 ↗
7. 10.1056/NEJMoa200203210.1056/NEJMoa2002032 ↗
8. 10.1001/jama.2020.158510.1001/jama.2020.1585 ↗
9. 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 ↗
10. 10.1038/s41591-020-0968-310.1038/s41591-020-0968-3 ↗
11. 10.1007/s00134-020-05985-910.1007/s00134-020-05985-9 ↗
12. Ameratunga R. · N. Z. Med. J. · 2020 · 133 · 7
13. 10.1016/j.cell.2020.02.05810.1016/j.cell.2020.02.058 ↗
14. 10.1016/j.cell.2020.04.00410.1016/j.cell.2020.04.004 ↗
15. 10.1007/s40262-013-0072-710.1007/s40262-013-0072-7 ↗
16. 10.1038/s41467-020-16048-410.1038/s41467-020-16048-4 ↗
17. 10.1016/j.celrep.2020.10852810.1016/j.celrep.2020.108528 ↗
18. 10.1016/j.kint.2018.01.02910.1016/j.kint.2018.01.029 ↗
19. 10.1001/jama.2018.034510.1001/jama.2018.0345 ↗
20. National Institute of Allergy and Infectious Diseases (NIAID) · 2020
21. 10.1038/s41586-020-2622-010.1038/s41586-020-2622-0 ↗
22. 10.1038/nrg376310.1038/nrg3763 ↗
23. 10.1016/j.addr.2020.12.01410.1016/j.addr.2020.12.014 ↗
24. 10.1021/acs.nanolett.0c0138610.1021/acs.nanolett.0c01386 ↗
25. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
26. 10.1039/D0BM01947J10.1039/D0BM01947J ↗
27. 10.1038/s41577-020-0343-010.1038/s41577-020-0343-0 ↗
28. 10.1016/S0140-6736(20)30937-510.1016/S0140-6736(20)30937-5 ↗
29. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
30. 10.1038/nbt.173310.1038/nbt.1733 ↗
31. 10.1016/j.ymthe.2019.05.01210.1016/j.ymthe.2019.05.012 ↗
32. 10.1021/acsnano.2c0564710.1021/acsnano.2c05647 ↗
33. 10.1007/s00432-007-0311-010.1007/s00432-007-0311-0 ↗
34. 10.1056/NEJMra160807710.1056/NEJMra1608077 ↗
35. 10.1136/thoraxjnl-2016-20917010.1136/thoraxjnl-2016-209170 ↗
36. 10.1056/NEJMc210217910.1056/NEJMc2102179 ↗
37. 10.1016/j.jviromet.2020.11399510.1016/j.jviromet.2020.113995 ↗
38. 10.1056/NEJMoa200776410.1056/NEJMoa2007764 ↗
39. 10.1056/NEJMoa202143610.1056/NEJMoa2021436 ↗
40. 10.1038/s41577-021-00542-x10.1038/s41577-021-00542-x ↗
41. 10.1038/s41421-021-00302-010.1038/s41421-021-00302-0 ↗
42. 10.1038/nm126710.1038/nm1267 ↗
43. 10.1038/nature0371210.1038/nature03712 ↗
44. 10.1016/S2213-2600(20)30418-510.1016/S2213-2600(20)30418-5 ↗
45. 10.1161/HYPERTENSIONAHA.109.13842010.1161/HYPERTENSIONAHA.109.138420 ↗
46. Fryar C. D. · NCHS Data Brief · 2017 · 289 · 1
47. 10.15585/mmwr.mm6912e210.15585/mmwr.mm6912e2 ↗
48. 10.1002/adma.20180511610.1002/adma.201805116 ↗
49. 10.15252/emmm.20211523010.15252/emmm.202115230 ↗
50. 10.15252/emmm.20201342610.15252/emmm.202013426 ↗
51. 10.1007/s12195-020-00619-y10.1007/s12195-020-00619-y ↗
52. 10.3390/pharmaceutics1211104210.3390/pharmaceutics12111042 ↗
53. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
54. 10.1016/j.isci.2021.10347910.1016/j.isci.2021.103479 ↗
55. 10.1056/NEJMoa210889110.1056/NEJMoa2108891 ↗
56. 10.1056/NEJMc210608310.1056/NEJMc2106083 ↗
57. 10.1038/s41586-021-03693-y10.1038/s41586-021-03693-y ↗
58. 10.3791/5226110.3791/52261 ↗
59. Van Hoecke L. · J Vis Exp · 2017 · 55398
60. 10.1038/s41598-021-87462-x10.1038/s41598-021-87462-x ↗
61. 10.3390/v1205051310.3390/v12050513 ↗
62. 10.1038/s41586-020-2179-y10.1038/s41586-020-2179-y ↗